The FDA enforcement report lists an ongoing Class II recall of dexmedetomidine hydrochloride in 0.9% sodium chloride injection, 400 µg per 100 mL — 4 µg/mL — in 100 mL single-dose containers manufactured by Baxter Healthcare. The stated reason is deviations from current good manufacturing practice.
Class II is the middle of the three FDA recall categories and means the agency judges that use of the product may cause temporary or medically reversible adverse consequences, with a remote probability of serious harm. The reason given is a process finding rather than a specific defect identified in the drug, and nothing in the notice indicates a problem with dexmedetomidine itself or with its licensed uses.
The exposure is concentrated where these bags are used most: intensive care sedation and procedural infusions, where a premixed ready-to-use bag is preferred precisely because it removes a dilution step. A unit that loses this presentation falls back to compounding from concentrate, which reintroduces the calculation error that the premixed bag was adopted to avoid. That is the practical risk here — not the recalled product, but the workaround.
This concerns an American manufacturer's premixed presentation. In Indian practice dexmedetomidine is supplied overwhelmingly as concentrate for dilution from several manufacturers, and CDSCO has made no corresponding statement, so supply here is not affected.
- Ask pharmacy whether your unit holds affected Baxter premixed dexmedetomidine bags
- If the premixed presentation is withdrawn, write down the dilution and the resulting concentration before the first bag is made up
- Double-check dexmedetomidine infusion rates for a week after any change of presentation — the units are easy to confuse
- Explain to the team that this is a manufacturing process recall, not a safety finding about the drug
- No action is needed for Indian supply; dexmedetomidine here is supplied as concentrate by other manufacturers
Why it matters
The hazard of losing a ready-to-use presentation is the reintroduced dilution step, not the recalled bag.
Don't overread it
A Class II recall for manufacturing deviations is a process finding, not evidence of harm from the drug.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for anaesthesiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free